Physician profile

Gray Smith

Family · Richmond, VA

NPI 1225503733

$822.91

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$202.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $246.78 2021-2023
Novo Nordisk INC $171.05 2021-2023 Wegovy
Boehringer Ingelheim Pharmaceuticals, INC. $135.69 2021-2023 Jardiance
Lilly USA, LLC $121.08 2021-2023 Mounjaro, Trulicity, Emgality
Amneal Pharmaceuticals LLC $37.34 2022
Dexcom, INC. $36.86 2022
Sanofi-Aventis U.S. LLC $23.60 2021-2022
Exact Sciences Corporation $20.80 2024 Cologuard Collection Kit
Abbott Laboratories $17.39 2023 Freestyle Libre 3
Dynavax Technologies Corporation $12.32 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gray Smith

$822.91

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/10863072/gray-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.